Arrowpoint Investment Partners’s Legend Biotech LEGN Stock Holding History

Arrowpoint Investment Partners’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$626K	Buy	+21,669	New	+$584K	0.14%	68

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Arrowpoint Investment Partners's LEGN Position: Q2 2026 in Review

Arrowpoint Investment Partners opened a new position in Legend Biotech (LEGN) in Q2 2026: 21,669 shares worth $626K. The stake represents 0.14% of the portfolio and ranks #68 among its holdings.

218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

Arrowpoint Investment Partners held 21,669 shares of Legend Biotech worth $626K as of Q2 2026.
Legend Biotech was a new Arrowpoint Investment Partners position in Q2 2026.
Legend Biotech made up 0.14% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #68 holding.
218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.